Turn Therapeutics Inc. TTRX 深 滬
已收盤 02-06 16:00:00 美东时间
3.85
+0.150
+4.05%
華盛通- 最 高3.92
- 今 開3.69
- 成交量 1.25万股
- 最 低 3.655
- 昨 收 3.70
- 總市值 1.13亿
- 52周最高 26.50
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 2.5701
- 委 比 0.00%
- 總股本 2944.52万
- 歷史最高 26.50
- 量 比 0.30
- 振 幅 7.16%
- 歷史最低 2.5701
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.
01-20 20:16
Turn Therapeutics appoints veteran executive to board
Turn Therapeutics Inc ( ($TTRX) ) has provided an update. On January 7, 2026, T...
01-08 05:51
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Turn Therapeutics has appointed Martin Dewurst, a seasoned life sciences and M&A professional with over 30 years of experience, to its Board of Directors. Dewurst, a former leader at McKinsey & Company and co-founder of the McKinsey Health Institute, brings expertise in biopharmaceuticals, medical technology, and global health. His加入 aligns with the company’s strategy to expand its pipeline and enhance long-term value through strategic acquisitio...
01-07 21:05
美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
D. Boral Capital Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $8
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $8.
2025-12-29 20:51
Turn Therapeutics Inc. Non-GAAP EPS of -$0.07
Turn Therapeutics Inc. press release (TTRX): Q3 Non-GAAP EPS of -$0.07. Research and Development (R&D) Expenses: Research and development expenses for the three months ended September 30, 2025 were $1...
2025-11-13 23:06
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics' GX-03 technology, targeting IL-36 and IL-31, has been recognized by *Patient Care Online* as a top innovation for atopic dermatitis treatment. This topical agent offers a novel mechanism addressing inflammation behind eczema and psoriasis, potentially reducing reliance on systemics and injectables. The company expects to release lead program data for severe eczema in early 2026. Turn Therapeutics also focuses on advancing wound...
2025-11-11 13:00
Turn Therapeutics signs license deal with surgical product supplier Medline
Turn Therapeutics (TTRX) has signed a global agreement with Medline, a company that supplies medical-surgical products and offers supply chain solutions. The details regarding financial terms, produ...
2025-10-30 21:51
Turn Therapeutics Enters Into Global Supply, Development, And License Agreement With Medline
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global
2025-10-30 19:36
